Medical oncology
21 – 30 of 618
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor : The AGITG ALT-GIST intergroup randomized phase II trial: Clinical Studies
- Contribution to journal › Article
-
Mark
Peripheral T- and natural killer-cell lymphomas : ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
- Contribution to journal › Article
-
Mark
Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies
- Contribution to journal › Article
-
Mark
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
- Contribution to journal › Article
-
Mark
Glucose-6-phosphate-dehydrogenase on old peroxisomes maintains self-renewal of epithelial stem cells after asymmetric cell division
- Contribution to journal › Article
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
- Contribution to journal › Article
-
Mark
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review
- Contribution to journal › Scientific review
-
Mark
Melanoma Proteomics Unveiled : Harmonizing Diverse Data Sets for Biomarker Discovery and Clinical Insights via MEL-PLOT
- Contribution to journal › Article
-
Mark
Temporal trends in relative survival of diffuse large B-cell lymphoma in Sweden and Denmark in the era of targeted and cellular therapies
- Contribution to journal › Letter
-
Mark
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma : a Danish population-based study
- Contribution to journal › Article
